<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11013-2014084 - 2S2UI</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Building lobby capacity to challenge pharmaceutical monopolies in South East Asia</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">APN+ is a peer-based advocacy organisation for people living with HIV in South East Asia. The project aims to strengthen communities in the Asia Pacific region to advocate for the elimination of intellectual property barriers. A key part of the program relates to harmful IP provisions in Free Trade agreements between developed and developing countries, with a specific focus on the Regional Cooperation Economic Partnership (RCEP) negotiations between 16 countries of the Asia-Pacific. Harsh IP provisions proposed by Japan in these negotiations are of grave concern to the future treatment access in the region. In addition, activities in Indonesia will focus on the implementation of compulsory licences, in Vietnam on repelling TRIPS-plus provisions in the TPP negotiations and on  advocacy for local production of HIV and Hepatitis C treatment. In Myanmar an IP law campaign will be launched to advocate for the full use of the TRIPS transition period.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">In the Asia Pacific Region, the number of people receiving antiretroviral treatment (ART) has increased steadily to an estimated 39% of all people eligible for ART according to 2010 WHO Guidelines. This progress has largely been made possible by the dramatic drop in antiretroviral (ARV) prices over the last ten years due to generic competition. However, the region continues to lag behind the average global treatment coverage level of 47%, and the annual number of new HIV infections cases is still 50% higher than the annual increase in the number of people receiving ART. In addition, most people in low and middle-income countries do not have access to the newer generation of treatment regimens.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Main outcomes:
# APN+ members strengthened in the 10 RCEP negotiating countries to advocate for the elimination of harmful TRIPS-plus provisions in the RCEP negotiations ensuring space for production, import and export of safe, effective and affordable medicines in the region.
# The implementation and use of patent flexibilities in Indonesia, leading to increased access to affordable treatment for Hepatitis C
# The full use of the TRIPS transition period in Myanmar and the education of stakeholders, like community groups, government, medical professionals on issues around medicine patents, intellectual property and medicine pricing for them to take a role in advocacy activities.
# The elimination of TRIPS-plus provisions in the ongoing Trans-Pacific Partnership Agreement (TPPA) Negotiations in Vietnam and the stimulation of local production of key ARVs and hepatitis treatment.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN"></narrative>
  </description>
  <participating-org role="4" type="23">
   <narrative xml:lang="EN">APN+</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2015-01-31" type="1"></activity-date>
  <activity-date iso-date="2018-01-30" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="ID" percentage="33.333333333333336"></recipient-country>
  <recipient-country code="MM" percentage="33.333333333333336"></recipient-country>
  <recipient-country code="VN" percentage="33.333333333333336"></recipient-country>
  <sector code="15160" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Building lobby capacity to challenge pharmaceutical monopolies in South East Asia Human rights</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2015-01-31"></period-start>
   <period-end iso-date="2018-01-30"></period-end>
   <value currency="EUR" value-date="2015-01-31">120000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">36000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014084</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">36000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014084</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-04-27"></transaction-date>
   <value currency="EUR" value-date="2016-04-27">30000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014084</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-04-27"></transaction-date>
   <value currency="EUR" value-date="2016-04-27">30000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014084</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-05-10"></transaction-date>
   <value currency="EUR" value-date="2017-05-10">30000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-05-11"></transaction-date>
   <value currency="EUR" value-date="2017-05-11">30000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-09-10"></transaction-date>
   <value currency="EUR" value-date="2017-09-10">14000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-09-11"></transaction-date>
   <value currency="EUR" value-date="2017-09-11">14000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-05-21"></transaction-date>
   <value currency="EUR" value-date="2018-05-21">7827</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-05-22"></transaction-date>
   <value currency="EUR" value-date="2018-05-22">7827</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">APN+</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
